Pandorum Technologies Raises $18 Million Series B to Advance Regenerative Medicine Innovation

Indian biotech startup Pandorum Technologies has secured $18 million in a Series B funding round, marking a significant step forward in its mission to develop next-generation regenerative medicine therapies. The round was led by Protons Corporate, with participation from Galentic Pharma, investor Ashish Kacholia, Noblevast Advisory, Avinya Fund, and members of the Burman Family, among others.

The fresh capital is expected to help the company accelerate research, expand clinical development programs, and strengthen its presence in both India and the United States. Founded by Tuhin Bhowmick and Arun Chandru, Pandorum Technologies operates at the intersection of biotechnology, tissue engineering, and regenerative medicine, focusing on innovative therapies that aim to repair and restore damaged human tissues.

A Growing Force in Regenerative Medicine

Pandorum Technologies has been building advanced solutions in the field of regenerative healthcare, a rapidly evolving sector that aims to help the body heal itself. The company specializes in programmable, exosome-based tissue regenerative therapies — a modern scientific approach that uses naturally occurring cellular particles to repair damaged cells and tissues.

Exosomes are tiny vesicles released by cells that carry biological signals. Scientists believe these signals can help trigger healing, reduce inflammation, and support tissue regeneration. Pandorum’s work focuses on using this science to develop therapies that could transform how chronic diseases, injuries, and organ damage are treated in the future.

The company’s research-driven model combines biotechnology, artificial intelligence, and tissue engineering to create therapies that are more precise and effective. With the new funding, Pandorum plans to expand its pipeline and accelerate the development of clinical-stage treatments.

Strong Investor Confidence in Deep Science

The participation of multiple well-known investors in the Series B round reflects growing confidence in India’s deep science and biotech ecosystem. Investors are increasingly recognizing the potential of companies working in advanced healthcare technologies, especially those with a global presence.

Pandorum already operates in both India and the United States, positioning itself as a cross-border innovation company. This dual presence allows it to access global research networks, talent pools, and clinical opportunities while continuing to build scientific capabilities in India.

The involvement of Protons Corporate as the lead investor signals strong support for the company’s long-term vision. Strategic investors from the pharmaceutical and healthcare sectors, such as Galentic Pharma, also bring industry knowledge that can support product development and commercialization.

Founders Driving Scientific Innovation

Co-founders Tuhin Bhowmick and Arun Chandru have been central to shaping Pandorum’s growth journey. Their focus has been on building a science-first company that can translate advanced research into real-world medical solutions.

Over the years, the company has worked on developing tissue regeneration platforms aimed at addressing unmet medical needs. Its research has explored solutions for conditions where existing treatments may be limited or unable to fully restore function.

With the new funding, the founders are expected to strengthen research capabilities, hire scientific talent, and push forward clinical programs that could bring regenerative therapies closer to patients.

The Rising Importance of Regenerative Healthcare

Globally, regenerative medicine is gaining attention as one of the most promising frontiers in healthcare. Traditional treatments often focus on managing symptoms, while regenerative therapies aim to repair or replace damaged tissues and organs.

This approach has the potential to transform treatment for chronic conditions, injuries, and age-related diseases. As populations age and healthcare needs grow, technologies that promote healing and recovery are becoming increasingly important.

India’s biotech sector has been expanding steadily, supported by a growing startup ecosystem, research institutions, and investor interest. Companies like Pandorum Technologies are helping position the country as an emerging hub for scientific innovation.

Strengthening India’s Global Biotech Presence

The success of funding rounds like this reflects a broader trend — Indian biotech startups are beginning to attract serious global attention. Investors are now looking beyond traditional technology sectors and exploring opportunities in healthcare innovation.

Pandorum’s focus on deep science and translational medicine sets it apart from many early-stage biotech companies. Its work in programmable tissue therapies represents a high-impact area that could reshape the future of medical treatment.

By operating across India and the US, the company is also building a bridge between scientific research and global healthcare markets. This approach helps accelerate innovation while ensuring that therapies can reach international patients.

Looking Ahead

The $18 million Series B funding marks an important milestone for Pandorum Technologies as it moves into its next phase of growth. The capital will help the company advance research programs, strengthen clinical development, and expand partnerships across the healthcare ecosystem.

As regenerative medicine continues to evolve, companies that can combine strong science with scalable innovation are likely to lead the next wave of healthcare breakthroughs. Pandorum’s focus on exosome-based therapies places it at the forefront of this transformation.

With growing investor support and a clear scientific vision, the company is taking meaningful steps toward developing treatments that could change how doctors approach healing and tissue repair. The journey ahead will require time, research, and collaboration, but the momentum behind Pandorum Technologies shows that the future of regenerative healthcare is steadily moving from the lab to real-world impact.